AgingResearch.NewsJoin free

Vector Y Therapeutics

CompanyNetherlands

Vector Y Therapeutics develops one asset, in phase 2 (VTx-002 in amyotrophic lateral sclerosis). Mostly gene therapy acting on TARDBP; based in Netherlands.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • VTx-002

    Delivers a vectorized antibody targeting pathological TDP-43 to promote its clearance.

    Phase 2, Gene therapy, TARDBP, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals1
  • Similar companies6

Intelligence